WallStreetZenWallStreetZen

NASDAQ: ADIL
Adial Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Be the first to know when Wall Street analysts revise their ADIL stock forecasts and price targets.

Forecast return on equity

Is ADIL forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.16%

Forecast return on assets

Is ADIL forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

ADIL revenue forecast

What is ADIL's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$46.4M
Avg 2 year Forecast
$93.8M
Avg 3 year Forecast
$142.3M

ADIL vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ADIL$1.73N/AN/A
KA$0.64$8.00+1,150.00%Buy
TOVX$0.41N/AN/A
TENX$3.60$30.00+733.33%Strong Buy
HEPA$1.29N/AN/A
View Top Biotech Stocks

Adial Pharmaceuticals Stock Forecast FAQ

What is ADIL's revenue growth forecast for 2026-2028?

(NASDAQ: ADIL) Adial Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.92%.

Adial Pharmaceuticals's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast ADIL's revenue for 2026 to be $188,064,453, with the lowest ADIL revenue forecast at $188,064,453, and the highest ADIL revenue forecast at $188,064,453. On average, 1 Wall Street analysts forecast ADIL's revenue for 2027 to be $380,427,059, with the lowest ADIL revenue forecast at $380,427,059, and the highest ADIL revenue forecast at $380,427,059.

In 2028, ADIL is forecast to generate $577,047,269 in revenue, with the lowest revenue forecast at $577,047,269 and the highest revenue forecast at $577,047,269.

If you're new to stock investing, here's how to buy Adial Pharmaceuticals stock.

What is ADIL's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: ADIL) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is ADIL's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: ADIL) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.